Kenvue Inc. (NYSE:KVUE) Plans $0.21 Quarterly Dividend

Kenvue Inc. (NYSE:KVUE) announced a quarterly dividend on Thursday, January 16th,Wall Street Journal reports. Shareholders of record on Wednesday, February 12th will be given a dividend of 0.205 per share on Wednesday, February 26th. This represents a $0.82 annualized dividend and a yield of 3.89%. The ex-dividend date is Wednesday, February 12th.

Kenvue has a payout ratio of 63.1% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Kenvue to earn $1.20 per share next year, which means the company should continue to be able to cover its $0.82 annual dividend with an expected future payout ratio of 68.3%.

Kenvue Stock Performance

Shares of NYSE KVUE traded down $0.09 during midday trading on Friday, hitting $21.11. 11,266,973 shares of the company’s stock were exchanged, compared to its average volume of 9,329,477. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $40.46 billion, a PE ratio of 38.37, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. Kenvue has a 12 month low of $17.67 and a 12 month high of $24.46. The company’s 50 day moving average price is $22.47 and its 200 day moving average price is $21.64.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.31 earnings per share. As a group, analysts predict that Kenvue will post 1.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Bank of America increased their price target on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Royal Bank of Canada raised Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. UBS Group decreased their price objective on Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a report on Thursday. Barclays dropped their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday. Finally, Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and upped their price target for the company from $21.00 to $26.00 in a research note on Monday, January 6th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Kenvue presently has an average rating of “Hold” and an average price target of $23.08.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.